MARKERS OF DOPAMINE METABOLISM IN PARKINSONS-DISEASE

被引:69
|
作者
LEWITT, PA
GALLOWAY, MP
MATSON, W
MILBURY, P
MCDERMOTT, M
SRIVASTAVA, DK
OAKES, D
机构
[1] WAYNE STATE UNIV,SCH MED,DEPT NEUROL,DETROIT,MI 48235
[2] WAYNE STATE UNIV,SCH MED,DEPT PSYCHIAT,DETROIT,MI 48235
[3] ESA INC,BEDFORD,MA
[4] UNIV ROCHESTER,DIV BIOSTAT,ROCHESTER,NY 14627
关键词
D O I
10.1212/WNL.42.11.2111
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We used two analytic methods (a multichannel coulometric electrode array with high-performance liquid chromatography, and gas chromatography-mass spectrophotometry) to measure CSF dopamine (DA) and its metabolites in mildly affected, unmedicated subjects with Parkinson's disease (PD). The mean (+/- SD) concentration of homovanillic acid (HVA), the most abundant product of DA turnover, was 164.57 +/- 95.05 nM. As sequential aliquots of CSF were collected from the first to 23rd ml, CSF HVA concentration almost doubled. After HVA, 3-0-methyldopa (3-0-MD) was the next most abundant compound. The summed concentrations of 3-0-MD, 3,4-dihydroxyphenylacetic acid, 3-methoxytyramine, DA, DA-3-sulfate, homovanillol, and levodopa (LD) amounted to 12.6% of HVA. Concentrations of the DA metabolites did not correlate to a variety of indices of PD severity. The presence of LD and 3-0-MD may be indicators of DA synthesis and possibly could reflect compensatory processes among surviving dopaminergic neurons of the PD brain.
引用
收藏
页码:2111 / 2117
页数:7
相关论文
共 50 条
  • [1] DOPAMINE AGONISTS IN PARKINSONS-DISEASE
    WOLTERS, EC
    TISSINGH, G
    BERGMANS, PLM
    KUIPER, MA
    [J]. NEUROLOGY, 1995, 45 (03) : 28 - 34
  • [2] DOPAMINE AGONISTS IN PARKINSONS-DISEASE
    DUBOIS, B
    AGID, Y
    [J]. REVUE DU PRATICIEN, 1986, 36 (05): : 207 - 214
  • [3] DOPAMINE, TREMOR, AND PARKINSONS-DISEASE
    HIRSCH, EC
    MOUATT, A
    FAUCHEUX, B
    BONNET, AM
    JAVOYAGID, F
    GRAYBIEL, AM
    AGID, Y
    [J]. LANCET, 1992, 340 (8811): : 125 - 126
  • [4] DOPAMINE AGONISTS IN PARKINSONS-DISEASE
    CALNE, DB
    BURTON, K
    BECKMAN, J
    MARTIN, WRW
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1984, 11 (01) : 221 - 224
  • [5] DOPAMINE AGONISTS AND PARKINSONS-DISEASE
    BURTON, K
    CALNE, DB
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 1984, 86 (03) : 172 - 177
  • [6] PARKINSONS-DISEASE, DOPAMINE, AND PERSONALITY
    MENZA, M
    FORMAN, NE
    GOLDSTEIN, HE
    GOLBE, LI
    [J]. ANNALS OF NEUROLOGY, 1989, 26 (01) : 125 - 125
  • [7] XENOBIOTIC METABOLISM IN PARKINSONS-DISEASE
    STEVENTON, GB
    HEAFIELD, MTE
    WARING, RH
    WILLIAMS, AC
    [J]. NEUROLOGY, 1989, 39 (07) : 883 - 887
  • [8] THE RETINAL DOPAMINE SYSTEM IN PARKINSONS-DISEASE
    NGUYENLEGROS, J
    HARNOIS, C
    DIPAOLO, T
    SIMON, A
    [J]. CLINICAL VISION SCIENCES, 1993, 8 (01): : 1 - 12
  • [9] PARKINSONS-DISEASE - BRAIN DOPAMINE RECEPTORS
    LEE, T
    SEEMAN, P
    RAJPUT, A
    FARLEY, I
    HORNYKIEWICZ, O
    [J]. FEDERATION PROCEEDINGS, 1978, 37 (03) : 382 - 382
  • [10] DOPAMINE CELL REPLACEMENT - PARKINSONS-DISEASE
    YUREK, DM
    SLADEK, JR
    [J]. ANNUAL REVIEW OF NEUROSCIENCE, 1990, 13 : 415 - 440